| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 27/08/2024 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD | NASDAQ:CLSD | Clearside Biomedical Inc |
| 12/08/2024 | 22:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CLSD | Clearside Biomedical Inc |
| 12/08/2024 | 22:15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CLSD | Clearside Biomedical Inc |
| 12/08/2024 | 22:05 | GlobeNewswire Inc. | Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:CLSD | Clearside Biomedical Inc |
| 08/08/2024 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference | NASDAQ:CLSD | Clearside Biomedical Inc |
| 01/08/2024 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024 | NASDAQ:CLSD | Clearside Biomedical Inc |
| 29/07/2024 | 22:05 | GlobeNewswire Inc. | Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China | NASDAQ:CLSD | Clearside Biomedical Inc |
| 22/07/2024 | 18:00 | GlobeNewswire Inc. | Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET | NASDAQ:CLSD | Clearside Biomedical Inc |
| 11/07/2024 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board | NASDAQ:CLSD | Clearside Biomedical Inc |
| 27/06/2024 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery | NASDAQ:CLSD | Clearside Biomedical Inc |
| 12/06/2024 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting | NASDAQ:CLSD | Clearside Biomedical Inc |
| 21/05/2024 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA® | NASDAQ:CLSD | Clearside Biomedical Inc |
| 10/05/2024 | 22:31 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:CLSD | Clearside Biomedical Inc |
| 09/05/2024 | 22:05 | GlobeNewswire Inc. | Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:CLSD | Clearside Biomedical Inc |
| 08/05/2024 | 22:15 | GlobeNewswire Inc. | Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference | NASDAQ:CLSD | Clearside Biomedical Inc |
| 30/04/2024 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 | NASDAQ:CLSD | Clearside Biomedical Inc |
| 16/04/2024 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors | NASDAQ:CLSD | Clearside Biomedical Inc |
| 02/04/2024 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:CLSD | Clearside Biomedical Inc |
| 18/03/2024 | 12:05 | GlobeNewswire Inc. | Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer | NASDAQ:CLSD | Clearside Biomedical Inc |
| 12/03/2024 | 21:05 | GlobeNewswire Inc. | Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | NASDAQ:CLSD | Clearside Biomedical Inc |
| 29/02/2024 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024 | NASDAQ:CLSD | Clearside Biomedical Inc |
| 08/02/2024 | 22:52 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:CLSD | Clearside Biomedical Inc |
| 07/02/2024 | 14:00 | GlobeNewswire Inc. | Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering | NASDAQ:CLSD | Clearside Biomedical Inc |
| 20/01/2024 | 00:25 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CLSD | Clearside Biomedical Inc |
| 19/01/2024 | 21:04 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CLSD | Clearside Biomedical Inc |
| 14/12/2023 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD | NASDAQ:CLSD | Clearside Biomedical Inc |
| 13/11/2023 | 22:05 | GlobeNewswire Inc. | Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update | NASDAQ:CLSD | Clearside Biomedical Inc |
| 08/11/2023 | 13:05 | GlobeNewswire Inc. | Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference | NASDAQ:CLSD | Clearside Biomedical Inc |
| 07/11/2023 | 22:20 | GlobeNewswire Inc. | Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting | NASDAQ:CLSD | Clearside Biomedical Inc |
| 03/11/2023 | 17:00 | GlobeNewswire Inc. | BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector® | NASDAQ:CLSD | Clearside Biomedical Inc |